Nivolumab in Patients With Type B3 Thymoma & Thymic Carcinoma (NIVOTHYM)

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06019468` - Neoadjuvant Treatment For Locally Advanced Thymic Cancer	Phase 2
Terminated	`NCT00818090` - Paclitaxel and Cisplatin for Thymic Neoplasm	Phase 2
Completed	`NCT02623127` - A Study of Sunitinib in Patients With Metastatic or Recurrent Thymic Carcinoma	Phase 2
Active, not recruiting	`NCT03921671` - Ramucirumab and Carbo-Paclitaxel for Untreated Thymic Carcinoma / B3 Thymoma With Carcinoma (RELEVENT)	Phase 2
Active, not recruiting	`NCT02364076` - Pembrolizumab and Epacadostat in Patients With Thymic Carcinoma	Phase 2
Terminated	`NCT01100944` - A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, Malignancies	Phase 1/Phase 2
Recruiting	`NCT03449173` - Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines (Style Trial)	Phase 2
Recruiting	`NCT03556228` - Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma	Phase 1
Completed	`NCT01364727` - A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies	Phase 2
Suspended	`NCT03463460` - Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer	Phase 2
Completed	`NCT00010257` - Carboplatin Combined With Paclitaxel in Treating Patients With Advanced Thymoma	Phase 2
Completed	`NCT04430842` - Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S	Phase 1
Active, not recruiting	`NCT03583086` - Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors	Phase 1/Phase 2
Completed	`NCT03517488` - A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors	Phase 1
Completed	`NCT00198133` - Phase II Study of Alimta (Pemetrexed) Treatment of Advanced Thymoma and Thymic Carcinoma	Phase 2
Recruiting	`NCT03170804` - Genomic Profiling of Nodular Thyroid Disease and Thyroid Cancer	N/A
Recruiting	`NCT05667948` - Molecular Analysis and Treatment Options of Thymic Malignancies
Terminated	`NCT01011439` - Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma	Phase 2
Terminated	`NCT01143545` - Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas	Phase 1
Completed	`NCT02307500` - Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy	Phase 2

NCT number	NCT03134118
Study type	Interventional
Source	European Organisation for Research and Treatment of Cancer - EORTC
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	April 11, 2018
Completion date	July 2024

Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM) — NIVOTHYM

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms